1. LINE

      Text:AAAPrint
      Sci-tech

      Australia begins production of Oxford-developed COVID-19 vaccine

      1
      2020-11-09 10:48:40Xinhua Editor : Cheng Zizhuo ECNS App Download
      Special: Battle Against Novel Coronavirus

      Australia commenced locally manufacturing a COVID-19 vaccine candidate developed by the University of Oxford from Monday, with roughly 30 million doses planned to be made.

      Despite still undergoing clinical trials, the vaccine, which was co-developed by pharmaceutical company AstraZeneca, is considered one of the more promising vaccines globally.

      Australian biotech firm CSL has agreements with AstraZeneca and the Australian government to begin pre-emptive production of the vaccine, for release during the first half of 2021 should remaining tests prove successful.

      "We are undertaking these manufacturing activities at-risk and in parallel with the clinical trials and approvals processes in recognition of the significant urgency of the COVID-19 pandemic," CSL's Chief Scientific Officer Andrew Nash said.

      It is expected the vaccine will require a two-dose per person regime meaning it could be effectively administered to 15 million people. However, it will not be released for use until the development process is reviewed and approved by Australia's government regulatory authority, the Therapeutic Goods Administration (TGA).

      Production will take place at CSL's bioreactor facility in the State of Victoria, with the manufacturing process beginning by thawing vials containing vaccine cells which had been frozen under liquid nitrogen.

      "After growing in the bioreactors, the vaccine is then filtered and purified leaving just the antigen, or vaccine product. It is then ready for final formulation and filling into dosage vials," the company said in a statement.

      CSL had already manufactured several doses of another COVID-19 vaccine candidate developed by Australia's University of Queensland (UQ), which it is holding in readiness to progress to Phase 2b/3 clinical trials.

      Further trials on the UQ vaccine candidate are due pending the release and review of Phase 1 clinical trial data.

      MorePhoto

      Most popular in 24h

      MoreTop news

      MoreVideo

      LINE
      Back to top Links | About Us | Jobs | Contact Us | Privacy Policy
      Copyright ©1999-2020 Chinanews.com. All rights reserved.
      Reproduction in whole or in part without permission is prohibited.
      主站蜘蛛池模板: 免费一看一级毛片| 久久99国产乱子伦精品免费| 在线观看人成网站深夜免费| 亚洲婷婷综合色高清在线| 免费A级毛片av无码| 亚洲AV乱码久久精品蜜桃| 成人无码WWW免费视频| 国产V亚洲V天堂无码久久久| 中文字幕手机在线免费看电影 | 亚洲最新永久在线观看| 无码人妻丰满熟妇区免费| 久久精品国产亚洲AV嫖农村妇女| 久久久久国产精品免费网站| 亚洲综合婷婷久久| 美女视频黄免费亚洲| 亚洲人成网站免费播放| 国产一级大片免费看| 一级黄色片免费观看| 国产专区一va亚洲v天堂| 国产免费一区二区三区不卡 | 亚洲精品国产福利一二区| gogo免费在线观看| 久久精品国产亚洲av成人| 1000部羞羞禁止免费观看视频| 亚洲日本在线播放| 日本一道综合久久aⅴ免费| 午夜亚洲国产精品福利| 最新国产AV无码专区亚洲| 免费人成视频在线观看网站| 国产成人亚洲精品| 亚洲成a人片在线播放| 午夜免费福利视频| 亚洲成av人在线观看网站| 亚洲色成人网站WWW永久| 最好看最新的中文字幕免费| 亚洲aⅴ天堂av天堂无码麻豆| 亚洲亚洲人成综合网络| 免费精品国产自产拍在| 亚洲精品国产日韩无码AV永久免费网| 亚洲国产精品国自产电影| 免费国产成人午夜电影|